WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006084058) METHOD FOR TREATING GEFITINIB RESISTANT CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/084058    International Application No.:    PCT/US2006/003717
Publication Date: 10.08.2006 International Filing Date: 02.02.2006
IPC:
A61K 31/00 (2006.01)
Applicants: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, Massachusetts 02114 (US) (For All Designated States Except US).
WYETH [US/US]; Five Giralda Farms, Madison, New Jersey 07940 (US) (For All Designated States Except US).
HABER, Daniel [US/US]; (US) (For US Only).
BELL, Daphne Winifred [US/US]; (US) (For US Only).
SETTLEMAN, Jeffrey E. [US/US]; (US) (For US Only).
SORDELLA, Raffaella [IT/US]; (US) (For US Only).
GODIN-HEYMANN, Nadia G. [US/US]; (US) (For US Only).
KWAK, Eunice L. [US/US]; (US) (For US Only).
RABINDRAN, Sridhar Krishna [IN/US]; (US) (For US Only)
Inventors: HABER, Daniel; (US).
BELL, Daphne Winifred; (US).
SETTLEMAN, Jeffrey E.; (US).
SORDELLA, Raffaella; (US).
GODIN-HEYMANN, Nadia G.; (US).
KWAK, Eunice L.; (US).
RABINDRAN, Sridhar Krishna; (US)
Agent: RESNICK, David; NIXON PEABODY LLP, 100 Summer Street, Boston, Massachusetts 02110 (US)
Priority Data:
60/649,483 03.02.2005 US
60/671,989 15.04.2005 US
Title (EN) METHOD FOR TREATING GEFITINIB RESISTANT CANCER
(FR) METHODE DE TRAITEMENT DU CANCER RESISTANT AU GEFITINIB
Abstract: front page image
(EN)The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
(FR)L'invention concerne des méthodes de traitement du cancer résistant au gefitinib et/ou à l'erlotinib. Un contrôle est effectué sur un individu atteint d'un cancer afin de surveiller la progression de la maladie après un traitement faisant intervenir du gefitinib et/ou de l'erlotinib. La progression du cancer indique que le cancer résiste au gefitinib et/ ou à l'erlotinib. Après la prise en compte de la progression de cancer, on administre au sujet une composition pharmaceutique comprenant un inhibiteur irréversible du récepteur du facteur de croissance épidermique (EGFR). Dans des modes de réalisation préférés, l'inhibiteur irréversible du EGFR est un inhibiteur de type EKB-569, HKI-272 et HKI-357.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)